IL-10 was confirmed to be highly expressed in various types of cancer, including ovarian cancer (Ahmad et al., 2018), lymphoma (Gupta et al., 2012), prostate cancer (Lin and Zhang, 2017), and GC (Fortis et al., 1996), which can downregulate the inflammatory cytokines IL-6 and IL-8. Here, CXCL8 is linked to prostate carcinoma.